MILLIPLEX^® Rat Cardiac Injury Panel 1 - Cardiotoxicity Multiplex Assay

Drug-induced cardiotoxicity can be life threatening and necessitates limiting an otherwise-effective treatment. In fact, cardiovascular toxicity has been reported to account for over 40% of drug candidate withdrawal in premarketing clinical trials. Many therapeutic agents have been reported to induce or exacerbate heart failure including anti-tumor medications, immunomodulating drugs, antidepressants, and calcium channel blocking agents to name a few. Conventional biomarkers of cardiotoxicity such as aspartate aminotransferase (AST), lactate dehydrogenase (LDH) and creatine kinase (CK) have gradually been withdrawn due to low tissue specificity. The number of cardiac-specific biomarkers adapted from clinical studies of cardiotoxicity continues to rise. The reverse translational application of these auspicious biomarkers in experimental animal models could improve the power of detection for diagnosis, helping to predict the occurrence of cardiotoxicity in humans. Emerging biomarkers of cardiac injury include multiple categories of proteins: characteristic muscle cell proteins (cTnI, cTnT, FABP3 and MYL3), cytosolic kinase (CKM), secreted heparin-binding protein (FSTL1) and metalloprotease inhibitor (TIMP1). Numerous studies have demonstrated elevated levels of these biomarkers in experimental animal blood samples.

In order to meet the increasing need to provide screening assays for experimental biomarkers of drug-induced cardiac injury in pre-clinical and translational research models, we have developed the MILLIPLEX^® Rat Cardiac Injury Bead Panel 1. This configurable 7-plex panel is the most versatile system available for cardiac injury screening in pre-clinical and translational research models.

The MILLIPLEX^® Rat Cardiac Injury Bead Panel 1 (RCI1MAG-87K) contains all the components necessary to simultaneous quantify any or all of the following 7 analytes in serum and plasma samples: Cardiac Troponin I (cTnI), Cardiac Troponin T (cTnT), Creatine Kinase, Muscle (CKM), Fatty Acid Binding Protein 3 (FABP3), Follistatin-like Protein 1 (FSTL1), Myosin Light Chain 3 (MYL3), Tissue Inhibitor of Metalloproteinase-1 (TIMP-1).

This kit uses a 96-well format, contains lyophilized standard cocktail and two quality controls, and can measure up to 38 serum or plasma samples in duplicate.

Panel Type: Toxicity

The MILLIPLEX^® MAP Rat Cardiac Injury Magnetic Bead Panel 1 is a configurable 7-plex kit for the quantification of cTnI, cTnT, CKM (MM-CK), FABP3, FSTL1, MYL3, and TIMP-1 in serum or plasma samples on the Luminex xMAP instrument platform.

Cross Reactivty
There was no or negligible cross-reactivity between the antibodies for an analyte and any of the other analytes within a panel.

Design your multiplex kit by choosing available analytes within this panel.

Everything you need in a single kit.

Rat Cardiac Injury Standard, 1 vial, lyophilized

Rat Cardiac Injury Quality Control 1, 1 vial, lyophilized

Rat Cardiac Injury Quality Control 2, 1 vial, lyophilized

Serum Matrix (0.08% Sodium Azide), 1 vial, lyophylized

Assay Buffer, 1 bottle, 30 mL

Wash Buffer, 10X (0.05% Proclin), 2 bottles, 30 mL ea

Rat Cardiac Injury Panel 1 Detection Antibodies, 1 bottle, 3.2 mL

Rat Cardiac Injury Panel 1 Antibody-Immobilized Beads (20X), 200 µL ea

Streptavidin-Phycoerythrin, 1 bottle, 3.2 mL

Mixing Bottle, 1 bottle

Sample Plate, 96 well format, 1 plate

2 Foil Plate Sealers

Recommended storage for kit components is 2 - 8°C.

Please contact Technical Service for linearity of dilution.

Please refer to Assay Protocol for individual analyte accuracy.

Sensitivity: Please see kit protocol for assay sensitivities of individual analytes.

MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.